A5 Laboratories Inc. (A5 Labs) announced that its previously announced patent application to protect its technology for the production of interferon-based products was accepted by the United States patent office. The company was granted the provisional patent number of US 61/400,719 with a patent filing date of August 2, 2010. The patent application was submitted in order to protect the company's new method for the production of therapeutic proteins and specifically A5 Labs lead product VI-1718 for the treatment of certain cancers, multiple sclerosis and viral infections.
"I am very pleased that the Unites States patent office has accepted our patent application. We believe that the granting of this provisional patent will protect our company's new technology for the production of our interferon-based products such as VI-1718. We look forward to the next steps in advancing our plans towards the development of these products," said Dr. Richard Azani, president and CEO of A5 Labs.
A5 Labs is a contract research based organization servicing the pharmaceutical and biotechnology companies in North America. The company utilizes its research capabilities to license and acquire novel biotechnology products for development and commercialization.
Source:Pharmabiz
No comments:
Post a Comment